AT&T, Inc. (NYSE: T) - For an in-depth report on AT&T, Inc. follow: www.BullTrends.com/stockquote/T
Shares of AT&T Inc. closed down a modest 2.42% on Tuesday with nearly 40 million shares traded. The company made headlines this week after it announced that it would be buying DirecTV in a deal worth about $48.5 billion. AT&T will pay DirecTV shareholders $95 per share. Including DirecTV's debt, the total transaction's value is about $67.1 billion.
NewLead Holdings Limited (NASDAQ: NEWL) - For an in-depth report on NewLead Holdings Limited follow: www.BullTrends.com/stockquote/NEWL
Shares of NEWL closed up nearly 70% on about 54.2 million shares traded on Tuesday. The stock was one of the biggest advancers on the NASDAQ. The company announced earlier in the week that its eco-type handysize vessel, Newlead Albion, had been delivered to the NewLead fleet. The vessel has capacity of 32,318 dwt. NewLead Holdings said the Newlead Albion is expected to generate $2 million EBITDA per year, assuming $1.73 million yearly OPEX.
Co-Signer, Inc. (OTCBB: COSR) - For an in-depth report on Co-Signer, Inc. follow: www.BullTrends.com/stockquote/COSR
Co-Signer Inc. closed down 36.24% on Tuesday with about 5.6 million shares traded. The stock was one of the biggest decliners in the OTCBB market and sank to a yearly low of $0.02 during intra-day trading. The company announced this week that its wholly-owned subsidiary, Co-Signer.com has continued to receive overwhelming tenant demand for its service product nationwide.
Ophthotech Corporation (NASDAQ: OPHT) - For an in-depth report on Ophthotech Corporation follow: www.BullTrends.com/stockquote/OPHT
Shares of OPHT closed up nearly 25% on Tuesday with nearly 3.5 million shares traded. The Company announced a licensing deal for lead experimental compound Fovista with Novartis. In the deal, Ophthotech will retain all rights to Fovista within the U.S. with Novartis licensing the rights to the drug potentially in all other countries. The deal could mean more than $1 billion in milestone and royalty payments for Ophthotech.
Disclosure: BullTrends.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.